Comprehensive Study Notes: Global and Domestic Drug Trends, Harm Reduction, and Firearms Legislation

Global Drug Prevalence and Epidemiological Trends

• Global Drug Use Scale: An estimated $292\text{ million}$ people (1 in 18 individuals aged 15–64, or $5.6\%$ of the global population) used an illicit drug in 2022, representing a $20\%$ increase over the prior decade partly driven by population growth.

• Substance Breakdown (Past-Year Users, 2022):

  • Cannabis: $228\text{ million}$

  • Opioids: $60\text{ million}$

  • Amphetamine-type stimulants (ATS): $30\text{ million}$

  • Cocaine: $23\text{ million}$

  • "Ecstasy" (MDMA): $20\text{ million}$

• Drug Use Disorders: Approximately $64\text{ million}$ people globally (1 in 81) suffer from drug use disorders, yet only about 1 in 11 receives treatment.

• Injecting Drug Use and Blood-Borne Pathogens:

  • $13.9\text{ million}$ people globally inject drugs (PWID).

  • $1.6\text{ million}$ ($11.6\%$) PWID are living with HIV (relative risk is 14 times higher than in the wider population).

  • $6.8\text{ million}$ ($49\%$) PWID are living with hepatitis C; liver disease caused by hepatitis C accounts for over half of all drug-attributed deaths.

• Post-COVID-19 Stimulant Rebound: Wastewater analysis and survey indicators confirm a marked post-pandemic surge in the consumption of stimulants, notably cocaine and MDMA, in Europe, North America, and Oceania.

Illicit Supply Chains, Cultivation Hubs, and Organized Crime

• Contraction of Afghan Opiates: Following the Taliban's April 2022 drug ban, opium production in Afghanistan fell by $95\%$ in 2023, driving a $74\%$ decline in global opium production to $1,990\,\text{tons}$; Afghan farm income dropped by $92\%$.

• Golden Triangle Nexus (Myanmar, Lao PDR, Thailand): Armed syndicates have largely shifted from opium to synthetic methamphetamine production, while diversifying into wildlife trafficking, timber theft, illegal mining, and financial cyber-fraud across special economic zones and border casinos.

• Environmental Degradation: Methamphetamine synthesis in the Golden Triangle generates an estimated $1,900\text{ to }3,800\,\text{tons}$ of hazardous chemical waste annually ($5\text{ to }10\,\text{kg}$ of toxic waste per $1\,\text{kg}$ of methamphetamine).

• Record Cocaine Production: Global illicit cocaine manufacture reached a record high of over $2,700\,\text{tons}$ (at $100\%$ purity) in 2022 across $355,000\,\text{ha}$ of coca cultivation in Colombia, Peru, and Bolivia. Large-scale trafficking has driven lethal gang violence in transit hubs (e.g., homicide rates in Ecuador multiplied fivefold between 2019 and 2022).

Synthetic Drugs, Novel Psychoactive Substances, and High-Potency Analogs

• Synthetic Flexibility: Illicit synthetic drugs require no fixed agricultural geography, utilize cheap chemical precursors, have short reaction cycles, and are manufactured in mobile clandestine laboratories worldwide.

• Near and Middle East Convergence: The market for illicit amphetamine ("captagon") centered in the Syrian Arab Republic and Lebanon is increasingly converging with methamphetamine transit routes into Gulf countries and Iraq.

• Potent Synthetic Opioids (Fentanyls and Nitazenes): Illicit fentanyls (50 to 100 times more potent than morphine) dominate North American overdose deaths. Highly potent benzimidazole synthetic opioids (nitazenes, including etonitazepyne and protonitazepyne) are emerging in Europe and Australasia, driving fatal poisonings.

• Proliferation of New Psychoactive Substances (NPS): 566 distinct NPS were detected globally in 2022 ($1,240$ cumulative since 1995), spanning synthetic cannabinoid receptor agonists (such as AMB-FUBINACA and 5F-ADB), synthetic cathinones (such as mephedrone, alpha-PVP, and eutylone), and novel sedatives.

• Ketamine Expansion: Non-medical ketamine supply and wastewater detection have risen sharply in Western and Central Europe, North America, and East and South-East Asia, frequently formulated into sensory-attractive cocktail concoctions ("pink cocaine", "tucibi").

Drug-Related Harms, Societal Costs, and the Right to Health

• Global Burden of Disease: Opioid use disorders account for $71\%$ of all disability-adjusted life years (DALYs) lost to drug use disorders globally and $69\%$ of direct drug-related fatalities.

• Societal Cost Breakdown: Economic impacts comprise tangible costs (healthcare services, loss of workplace productivity, property crime, policing, judicial and correctional administration) and intangible costs (premature loss of life and reduced quality of life).

• Right to Health Dimensions: Grounded in fundamental human rights, public health frameworks require accessible, acceptable, voluntary, and evidence-based medical treatments and harm reduction services without stigma, discrimination, or compulsory detention.

Gender Dynamics and Disproportionate Harms

• Prevalence by Sex: Men constitute over three-quarters of people who use illicit drugs globally and roughly $90\%$ of drug law arrestees.

• Treatment Disparities: Women represent $25\%$ of amphetamine users but only $16\%$ of patients in ATS treatment; globally, only 1 in 18 women with drug use disorders receives care, compared to 1 in 7 men.

• Heightened Clinical Harm: Women who inject drugs are 1.2 times more likely to be living with HIV than male peers, experience accelerated progression to dependence, and face structural barriers including stigma, fear of losing child custody, and gender-based violence.

Drug Use, Overdose Mortality, and Harm Reduction in New Zealand

• National Prevalence Rates (2020/21):

  • Alcohol: $78.5\%$ annual use; $19.5\%$ drink hazardously ($40.5\%$ among youth aged 18–24).

  • Cannabis: $15.3\%$ annual use; $4.5\%$ use weekly or more.

  • Tobacco: $9.4\%$ daily smoking prevalence.

  • Amphetamines / Methamphetamine: $1.2\%$ annual prevalence (holding steady for a decade).

• Accidental Overdose Trends (2016–2023): 1,179 accidental overdose deaths were recorded in New Zealand between 2016 and 2023. Apart from a temporary peak in 2018 caused by the synthetic cannabinoid crisis, fatal overdoses have trended upward (reaching 188 deaths in 2023).

• Substances Implicated: Opioids are the leading cause (516 deaths), followed by alcohol (208) and benzodiazepines (141). Over $50\%$ of closed fatal cases involved four or more substances, and $90.7\%$ of closed opioid overdoses involved concurrent depressant use.

• Ethnic and Demographic Inequities: The annual accidental drug overdose mortality rate for Māori is 2.4 times higher than for non-Māori ($4.5$ vs $1.9$ deaths per $100,000$); Māori hospital poisoning presentations are 1.84 times the non-Māori rate.

• Harm Reduction Initiatives:

  • Drug Checking: New Zealand permanently legalised drug checking under the Drug and Substance Checking Legislation Act 2021; testing identifies dangerous contaminants like synthetic cathinones sold as MDMA.

  • Needle Exchange Programme: Distributes nearly $4\text{ million}$ sterile needles annually, maintaining national HIV prevalence among PWID at $0.2\%$

  • Community & Surveillance Programs: High Alert early-warning system; Te Ara Oranga health-police referral model in Northland and Eastern Bay of Plenty.

Drug Policy, Decriminalisation Models, and International Conventions

• Evolution of International Conventions:

  • 1912 International Opium Convention (4 substances controlled).

  • 1925 International Opium Convention (7 substances controlled, included cannabis export controls).

  • 1931 Convention (17 substances; limited manufacture strictly to medical and scientific use).

  • 1961 Single Convention on Narcotic Drugs (85 substances; established Schedules I–IV, covering opium, coca, and cannabis).

  • 1971 Convention on Psychotropic Substances (130 substances; added synthetic stimulants, hallucinogens, and sedatives).

  • 1988 United Nations Convention Against Illicit Traffic (220 substances; targeted drug trafficking syndicates, precursor chemicals, and money laundering).

  • UNGASS shifts: 1998 target of "a drug-free world" evolved by 2016 to a focus on a world "free of drug abuse" and flexible national health priorities.

• New Zealand Statutory Framework:

  • Misuse of Drugs Act 1975 (MODA): Drugs scheduled under Class A (very high risk), Class B (high risk), and Class C (moderate risk).

  • Misuse of Drugs Amendment Act 2019:

  • Empowered the Minister to issue Temporary Class Drug Orders (sections 4C–4G) published in the Gazette, treating newly emerging substances as Class C controlled drugs for up to 1 year (renewable once).

  • Classified synthetic cannabinoids AMB-FUBINACA and 5F-ADB directly into Schedule 1 as Class A controlled drugs.

  • Codified statutory prosecutorial discretion in sections 7(5) and 7(6), affirming that possession/use offences should not be prosecuted unless required in the public interest, directing police to consider whether a health-centred or therapeutic approach is more beneficial.

  • Cannabis Referendum (2020): A proposal to legalise and regulate adult-use recreational cannabis was rejected ($50.7\%$ "no" to $48.4\%$ "yes").

• Global Decriminalisation and Regulation Models:

  • Portugal: Decriminalised personal possession of all drugs in 2001, redirecting users to multidisciplinary Dissuasion Commissions.

  • Recreational Cannabis: Fully legalised commercial or non-commercial supply chains in Canada, Uruguay, 27 US states, Germany, Malta, and Luxembourg.

  • Psychedelic Renaissance: Clinical and policy shifts permitting medical or supervised therapeutic applications of psilocybin and MDMA in jurisdictions like Australia and parts of the United States and Canada.

New Zealand Firearms Prohibitions: Arms Amendment Act 2019

• Legislative Objective: Passed following the Christchurch mosque shootings to remove military-style semi-automatic firearms and high-capacity magazines from general circulation.

• Prohibited Firearms (Section 2A):

  • All semi-automatic firearms (except pistols), excluding rimfire firearms of $0.22$ calibre or less with magazines holding $\,\le 10$ cartridges, and semi-automatic shotguns with non-detachable tubular magazines holding $\,\le 5$ cartridges.

  • Pump-action shotguns capable of using detachable magazines or fitted with non-detachable tubular magazines holding $> 5$ cartridges.

• Prohibited Magazines (Section 2B): Shotgun magazines holding $> 5$ cartridges; any other firearm magazine capable of holding $> 10$ cartridges (or holding $> 10$ rimfire cartridges of $0.22$ calibre or less).

• Prohibited Parts and Ammunition (Sections 2C & 2D): Any component designed to enable semi-automatic or automatic fire actions, and ammunition declared prohibited by Order in Council.

• Exempt Classifications (Section 4A): Licensed dealers, bona fide collectors, museum curators, theatrical/broadcast productions, and professional wild animal/pest controllers operating under the Wildlife Act 1953, Wild Animal Control Act 1977, Conservation Act 1987, or Biosecurity Act 1993.

• Amnesty and Surrender Provisions: Established a statutory buy-back and surrender amnesty window until 30 September 2019 (sections 59A and 59B), granting police discretion not to prosecute unauthorized possession when items are surrendered in good faith.